We are live on ! Find out more
ASND icon

Ascendis Pharma A/S
ASND

203 hedge funds and large institutions have $8.28B invested in Ascendis Pharma A/S in 2024 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 75 increasing their positions, 67 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

65% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 23

12% more repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 67

7% more funds holding

Funds holding: 189 → 203 (+14)

6% more funds holding in top 10

Funds holding in top 10: 16 → 17 (+1)

0.19% less ownership

Funds ownership: 105.35% → 105.16% (-0.19%)

10% less capital invested

Capital invested by funds: $9.19B → $8.28B (-$914M)

52% less call options, than puts

Call options by funds: $21.1M | Put options by funds: $43.9M

Holders
203
Holders Change
+14
Holders Change %
+7.41%
% of All Funds
2.93%
Holding in Top 10
17
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+6.25%
% of All Funds
0.25%
New
38
Increased
75
Reduced
67
Closed
23
Calls
$21.1M
Puts
$43.9M
Net Calls
-$22.8M
Net Calls Change
-$19.3M

Top Buyers

1
Westfield Capital Management
Westfield Capital Management
Massachusetts
+$121M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$83.1M
3
Ameriprise
Ameriprise
Minnesota
+$82.4M
4
Fidelity International
Fidelity International
Bermuda
+$58.7M
5
ACA
Avoro Capital Advisors
New York
+$31.3M

Top Sellers

1
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
-$345M
2
Artisan Partners
Artisan Partners
Wisconsin
-$187M
3
Brown Advisory
Brown Advisory
Maryland
-$27.9M
4
TD Asset Management
TD Asset Management
Ontario, Canada
-$18.6M
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$18.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
SEC
101
Seven Eight Capital
New York
$2.17M +$1.53M +11,279 +245%
PL
102
Parkwood LLC
Ohio
$1.87M +$197K +1,449 +12%
NFGH
103
Nan Fung Group Holdings
Hong Kong
$1.85M – – –
Handelsbanken Fonder
104
Handelsbanken Fonder
Sweden
$1.84M +$163K +1,200 +10%
Stifel Financial
105
Stifel Financial
Missouri
$1.79M -$7.21K -53 -0.4%
SIA
106
Sit Investment Associates
Minnesota
$1.76M +$1.75M +12,880 New
Nomura Asset Management
107
Nomura Asset Management
Japan
$1.72M -$177K -1,300 -9%
CP
108
CenterBook Partners
Connecticut
$1.49M +$1.48M +10,905 New
NIM
109
NEOS Investment Management
Connecticut
$1.48M -$43.9K -323 -3%
Envestnet Asset Management
110
Envestnet Asset Management
Illinois
$1.45M +$862K +6,333 +147%
Wells Fargo
111
Wells Fargo
California
$1.45M -$61.4K -451 -4%
LP
112
LMR Partners
United Kingdom
$1.36M +$1.36M +10,000 New
SAM
113
Simplify Asset Management
Nevada
$1.21M +$1.21M +8,877 New
PNC Financial Services Group
114
PNC Financial Services Group
Pennsylvania
$1.21M -$381K -2,801 -24%
CIBC Private Wealth Group
115
CIBC Private Wealth Group
Georgia
$1.14M – – –
JF
116
Jump Financial
Illinois
$1.13M -$191K -1,406 -14%
Mirae Asset Global Investments
117
Mirae Asset Global Investments
South Korea
$1.11M -$688K -5,060 -38%
BCM
118
Bayesian Capital Management
New York
$1.09M +$1.09M +8,013 New
AWM
119
Avior Wealth Management
Nebraska
$1.09M +$20.4K +150 +2%
Royal Bank of Canada
120
Royal Bank of Canada
Ontario, Canada
$1.02M +$40.5K +298 +4%
AGP
121
Artia Global Partners
Florida
$1.01M -$1.15M -8,454 -53%
EGM
122
Engineers Gate Manager
New York
$969K +$85.3K +627 +10%
HWAM
123
Hennion & Walsh Asset Management
New Jersey
$951K -$8.03K -59 -0.8%
OAM
124
Oppenheimer Asset Management
New York
$945K +$279K +2,048 +42%
CUAMC
125
China Universal Asset Management Company
China
$928K -$574K -4,216 -38%
3 4
5
6 7

ASND Hedge Fund Activity: Q2 2024 in Review

203 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q2 2024, worth a combined $8.28B — down 9.9% from $9.19B a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new ASND positions and 23 closed out — a net gain of 15 holders — while 75 added to existing stakes and 67 trimmed.

The largest buyer was Westfield Capital Management, adding an estimated $121M. The largest seller was T. Rowe Price Investment Management, cutting an estimated $345M.

  • 203 institutional investors held Ascendis Pharma A/S (ASND) as of Q2 2024, up from 189 in Q1 2024.
  • Funds reported $8.28B of Ascendis Pharma A/S stock for Q2 2024, down 9.9% quarter-over-quarter.
  • 38 funds opened new Ascendis Pharma A/S positions in Q2 2024 and 23 closed out, a net change of +15 holders.
  • The largest Ascendis Pharma A/S buyer in Q2 2024 was Westfield Capital Management, an estimated $121M added.
  • The largest Ascendis Pharma A/S seller in Q2 2024 was T. Rowe Price Investment Management, an estimated $345M sold.

Based on aggregated 13F filings for Q2 2024.